These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11808830)

  • 1. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction.
    Kovarik JM; Kalbag J; Figueiredo J; Rouilly M; Frazier OL; Rordorf C
    J Clin Pharmacol; 2002 Jan; 42(1):95-9. PubMed ID: 11808830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.
    van Mourik ID; Thomson M; Kelly DA
    Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus.
    Kovarik JM; Noe A; Wang Y; Mueller I; DeNucci G; Schmouder RL
    Eur J Clin Pharmacol; 2006 May; 62(5):361-6. PubMed ID: 16547714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
    Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
    Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
    Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
    Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral.
    Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R
    Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis.
    Elder CA; Moore M; Chang CT; Jin J; Charnick S; Nedelman J; Cohen A; Guzzo C; Lowe N; Simpson K
    J Clin Pharmacol; 1995 Sep; 35(9):865-75. PubMed ID: 8786246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure.
    Kovarik JM; Eisen H; Dorent R; Mancini D; Vigano M; Rouilly M; Hsu CH; Rordorf C
    J Heart Lung Transplant; 2003 Oct; 22(10):1117-25. PubMed ID: 14550821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants.
    Kovarik JM; Hartmann S; Figueiredo J; Rordorf C; Golor G; Lison A; Budde K; Neumayer HH
    Pharmacotherapy; 2002 Feb; 22(2):154-9. PubMed ID: 11837553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporine bioequivalence study: quantification using fluorescence polarization immunoassay (FPIA) and radioimmunoassay (RIA).
    Mendes GD; de Oliveira CH; Sucupira M; Donato JL; Moreno RA; De Nucci G
    Int J Clin Pharmacol Ther; 2004 Feb; 42(2):125-32. PubMed ID: 15180174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.
    Kovarik JM; Hartmann S; Hubert M; Berthier S; Schneider W; Rosenkranz B; Rordorf C
    J Clin Pharmacol; 2002 Feb; 42(2):222-8. PubMed ID: 11831546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation.
    Mueller EA; Kovarik JM; van Bree JB; Lison AE; Kutz K
    Transplantation; 1994 Apr; 57(8):1178-82. PubMed ID: 8178343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the pharmacokinetics of cyclosporine in patients following long-term administration after a kidney transplant: comparison of Neoral and Sandimmune.
    Takahara S; Ichimaru N; Kojima Y; Namba Y; Toki K; Shi Y; Yoshimura K; Matsumiya K; Nonomura N; Okuyama A
    Transplant Proc; 2004 Mar; 36(2 Suppl):456S-460S. PubMed ID: 15041387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus drug interactions: application of a classification system for clinical decision making.
    Kovarik JM; Beyer D; Schmouder RL
    Biopharm Drug Dispos; 2006 Dec; 27(9):421-6. PubMed ID: 16955532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors.
    Akhlaghi F; Keogh AM; McLachlan AJ; Kaan A
    J Heart Lung Transplant; 2001 Apr; 20(4):431-8. PubMed ID: 11295581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics.
    Kovarik JM; Noe A; Berthier S; McMahon L; Langholff WK; Marion AS; Hoyer PF; Ettenger R; Rordorf C
    J Clin Pharmacol; 2003 Feb; 43(2):141-7. PubMed ID: 12616666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited sampling model for area-under-the-curve monitoring in pediatric patients receiving either Sandimmune or Neoral cyclosporin A oral formulations.
    Medeiros M; Pérez-Urizar J; Muñoz R; Castañeda-Hernández G
    Pediatr Transplant; 1999 Aug; 3(3):225-30. PubMed ID: 10487284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation.
    Meier-Kriesche HU; Kaplan B; Brannan P; Kahan BD; Portman RJ
    Ther Drug Monit; 1998 Aug; 20(4):401-7. PubMed ID: 9712465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.